Cargando…

A Potential of an Anti-HTLV-I gp46 Neutralizing Monoclonal Antibody (LAT-27) for Passive Immunization against Both Horizontal and Mother-to-Child Vertical Infection with Human T Cell Leukemia Virus Type-I

Although the number of human T-cell leukemia virus type-I (HTLV-I)-infected individuals in the world has been estimated at over 10 million, no prophylaxis vaccines against HTLV-I infection are available. In this study, we took a new approach for establishing the basis of protective vaccines against...

Descripción completa

Detalles Bibliográficos
Autores principales: Fujii, Hideki, Shimizu, Mamoru, Miyagi, Takuya, Kunihiro, Marie, Tanaka, Reiko, Takahashi, Yoshiaki, Tanaka, Yuetsu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4776196/
https://www.ncbi.nlm.nih.gov/pubmed/26848684
http://dx.doi.org/10.3390/v8020041
_version_ 1782419111404371968
author Fujii, Hideki
Shimizu, Mamoru
Miyagi, Takuya
Kunihiro, Marie
Tanaka, Reiko
Takahashi, Yoshiaki
Tanaka, Yuetsu
author_facet Fujii, Hideki
Shimizu, Mamoru
Miyagi, Takuya
Kunihiro, Marie
Tanaka, Reiko
Takahashi, Yoshiaki
Tanaka, Yuetsu
author_sort Fujii, Hideki
collection PubMed
description Although the number of human T-cell leukemia virus type-I (HTLV-I)-infected individuals in the world has been estimated at over 10 million, no prophylaxis vaccines against HTLV-I infection are available. In this study, we took a new approach for establishing the basis of protective vaccines against HTLV-I. We show here the potential of a passively administered HTLV-I neutralizing monoclonal antibody of rat origin (LAT-27) that recognizes epitopes consisting of the HTLV-I gp46 amino acids 191–196. LAT-27 completely blocked HTLV-I infection in vitro at a minimum concentration of 5 μg/mL. Neonatal rats born to mother rats pre-infused with LAT-27 were shown to have acquired a large quantity of LAT-27, and these newborns showed complete resistance against intraperitoneal infection with HTLV-I. On the other hand, when humanized immunodeficient mice were pre-infused intravenously with humanized LAT-27 (hu-LAT-27), all the mice completely resisted HTLV-I infection. These results indicate that hu-LAT-27 may have a potential for passive immunization against both horizontal and mother-to-child vertical infection with HTLV-I.
format Online
Article
Text
id pubmed-4776196
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-47761962016-03-09 A Potential of an Anti-HTLV-I gp46 Neutralizing Monoclonal Antibody (LAT-27) for Passive Immunization against Both Horizontal and Mother-to-Child Vertical Infection with Human T Cell Leukemia Virus Type-I Fujii, Hideki Shimizu, Mamoru Miyagi, Takuya Kunihiro, Marie Tanaka, Reiko Takahashi, Yoshiaki Tanaka, Yuetsu Viruses Article Although the number of human T-cell leukemia virus type-I (HTLV-I)-infected individuals in the world has been estimated at over 10 million, no prophylaxis vaccines against HTLV-I infection are available. In this study, we took a new approach for establishing the basis of protective vaccines against HTLV-I. We show here the potential of a passively administered HTLV-I neutralizing monoclonal antibody of rat origin (LAT-27) that recognizes epitopes consisting of the HTLV-I gp46 amino acids 191–196. LAT-27 completely blocked HTLV-I infection in vitro at a minimum concentration of 5 μg/mL. Neonatal rats born to mother rats pre-infused with LAT-27 were shown to have acquired a large quantity of LAT-27, and these newborns showed complete resistance against intraperitoneal infection with HTLV-I. On the other hand, when humanized immunodeficient mice were pre-infused intravenously with humanized LAT-27 (hu-LAT-27), all the mice completely resisted HTLV-I infection. These results indicate that hu-LAT-27 may have a potential for passive immunization against both horizontal and mother-to-child vertical infection with HTLV-I. MDPI 2016-02-03 /pmc/articles/PMC4776196/ /pubmed/26848684 http://dx.doi.org/10.3390/v8020041 Text en © 2016 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons by Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Fujii, Hideki
Shimizu, Mamoru
Miyagi, Takuya
Kunihiro, Marie
Tanaka, Reiko
Takahashi, Yoshiaki
Tanaka, Yuetsu
A Potential of an Anti-HTLV-I gp46 Neutralizing Monoclonal Antibody (LAT-27) for Passive Immunization against Both Horizontal and Mother-to-Child Vertical Infection with Human T Cell Leukemia Virus Type-I
title A Potential of an Anti-HTLV-I gp46 Neutralizing Monoclonal Antibody (LAT-27) for Passive Immunization against Both Horizontal and Mother-to-Child Vertical Infection with Human T Cell Leukemia Virus Type-I
title_full A Potential of an Anti-HTLV-I gp46 Neutralizing Monoclonal Antibody (LAT-27) for Passive Immunization against Both Horizontal and Mother-to-Child Vertical Infection with Human T Cell Leukemia Virus Type-I
title_fullStr A Potential of an Anti-HTLV-I gp46 Neutralizing Monoclonal Antibody (LAT-27) for Passive Immunization against Both Horizontal and Mother-to-Child Vertical Infection with Human T Cell Leukemia Virus Type-I
title_full_unstemmed A Potential of an Anti-HTLV-I gp46 Neutralizing Monoclonal Antibody (LAT-27) for Passive Immunization against Both Horizontal and Mother-to-Child Vertical Infection with Human T Cell Leukemia Virus Type-I
title_short A Potential of an Anti-HTLV-I gp46 Neutralizing Monoclonal Antibody (LAT-27) for Passive Immunization against Both Horizontal and Mother-to-Child Vertical Infection with Human T Cell Leukemia Virus Type-I
title_sort potential of an anti-htlv-i gp46 neutralizing monoclonal antibody (lat-27) for passive immunization against both horizontal and mother-to-child vertical infection with human t cell leukemia virus type-i
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4776196/
https://www.ncbi.nlm.nih.gov/pubmed/26848684
http://dx.doi.org/10.3390/v8020041
work_keys_str_mv AT fujiihideki apotentialofanantihtlvigp46neutralizingmonoclonalantibodylat27forpassiveimmunizationagainstbothhorizontalandmothertochildverticalinfectionwithhumantcellleukemiavirustypei
AT shimizumamoru apotentialofanantihtlvigp46neutralizingmonoclonalantibodylat27forpassiveimmunizationagainstbothhorizontalandmothertochildverticalinfectionwithhumantcellleukemiavirustypei
AT miyagitakuya apotentialofanantihtlvigp46neutralizingmonoclonalantibodylat27forpassiveimmunizationagainstbothhorizontalandmothertochildverticalinfectionwithhumantcellleukemiavirustypei
AT kunihiromarie apotentialofanantihtlvigp46neutralizingmonoclonalantibodylat27forpassiveimmunizationagainstbothhorizontalandmothertochildverticalinfectionwithhumantcellleukemiavirustypei
AT tanakareiko apotentialofanantihtlvigp46neutralizingmonoclonalantibodylat27forpassiveimmunizationagainstbothhorizontalandmothertochildverticalinfectionwithhumantcellleukemiavirustypei
AT takahashiyoshiaki apotentialofanantihtlvigp46neutralizingmonoclonalantibodylat27forpassiveimmunizationagainstbothhorizontalandmothertochildverticalinfectionwithhumantcellleukemiavirustypei
AT tanakayuetsu apotentialofanantihtlvigp46neutralizingmonoclonalantibodylat27forpassiveimmunizationagainstbothhorizontalandmothertochildverticalinfectionwithhumantcellleukemiavirustypei
AT fujiihideki potentialofanantihtlvigp46neutralizingmonoclonalantibodylat27forpassiveimmunizationagainstbothhorizontalandmothertochildverticalinfectionwithhumantcellleukemiavirustypei
AT shimizumamoru potentialofanantihtlvigp46neutralizingmonoclonalantibodylat27forpassiveimmunizationagainstbothhorizontalandmothertochildverticalinfectionwithhumantcellleukemiavirustypei
AT miyagitakuya potentialofanantihtlvigp46neutralizingmonoclonalantibodylat27forpassiveimmunizationagainstbothhorizontalandmothertochildverticalinfectionwithhumantcellleukemiavirustypei
AT kunihiromarie potentialofanantihtlvigp46neutralizingmonoclonalantibodylat27forpassiveimmunizationagainstbothhorizontalandmothertochildverticalinfectionwithhumantcellleukemiavirustypei
AT tanakareiko potentialofanantihtlvigp46neutralizingmonoclonalantibodylat27forpassiveimmunizationagainstbothhorizontalandmothertochildverticalinfectionwithhumantcellleukemiavirustypei
AT takahashiyoshiaki potentialofanantihtlvigp46neutralizingmonoclonalantibodylat27forpassiveimmunizationagainstbothhorizontalandmothertochildverticalinfectionwithhumantcellleukemiavirustypei
AT tanakayuetsu potentialofanantihtlvigp46neutralizingmonoclonalantibodylat27forpassiveimmunizationagainstbothhorizontalandmothertochildverticalinfectionwithhumantcellleukemiavirustypei